bci

SCHEDULE

PRELIMINARY PROGRAMME

SCIENTIFIC SESSION 4 – Gene Therapies
Chairs: Luigi Naldini, Flora Peyvandi
09.00 Addressing vector immunogenicity in the development of AAV-based gene therapies for bleeding disorders
Federico Mingozzi, France
09.30 Liver-directed lentiviral gene therapy of hemophilia
Luigi Naldini, Italy
10.00 An update on UCL/St Jude Haemophilia studies; successes and obstacles ahead
Amit Nathwani, UK
10.30 Gene therapy in hemophilia A
Wing Yen Wong, USA
11.00 Break & Poster Session
VIEW PAGE
SCIENTIFIC SESSION 5 – Von Willebrand factor
Chairs: Pier Mannuccio Mannucci, Denisa Wagner
11.30 Von Willebrand factor in ischemic stroke
Simon de Meyer, France
12.00 Interplay between von Willebrand factor, ADAMTS13 and NETs
Denisa Wagner, USA
SATELLITE SYMPOSIA / LECTURE
12.30 Satellite Lecture Sponsored by Roche
Haemophilia A: can we raise our treatment expectations?
Chair: David Lillicrap, Canada. Speaker: Elena Santagostino, Italy
13.00 Lunch & Poster Session
VIEW PAGE
14.30 Satellite Lecture Sponsored by Kedrion-LFB
How to choose FVIII products in newly treated patients with severe hemophilia A: before and after SIPPET
Chair: Johannes B. Oldenburg, Germany. Speaker: Pier Mannuccio Mannucci, Italy
15.00 Satellite Symposium Sponsored by Shire
Recombinant von Willebrand Factor: An Innovative Therapeutic Option for Difficult to Control Bleeds
VIEW PAGE
16.00 Break & Poster Session
VIEW PAGE
SCIENTIFIC SESSION 6 – Von Willebrand factor and disease
Chairs: Robert Montgomery, Zaverio M. Ruggeri
16.30 Old concepts and new functions of von Willebrand factor: 2017
Zaverio M. Ruggeri, USA
17.00 Von Willebrand factor regulation and role in disease
José Lopez, USA
17.30 Collagen and von Willebrand factor interactions and beyond
Veronica Flood, USA
18.00 The genetics of von Willebrand disease
Ann Goodeve, UK
18.30 The many faces of thrombocytopenia in von Willebrand disease type 2B
Cecile Denis, France